Osteoporosis Drugs Market in BRIC Nations 2015-2019

Market outlook of the osteoporosis drugs market in BRIC nations

The growing prevalence of osteoporosis coupled with the rise in awareness of diagnosis and treatment, has paved the need to develop new drugs with increased safety and efficacy profiles that encourage bone building. This growing demand will help boost the osteoporosis drugs market in BRIC nations, which is expected to grow moderately and post a CAGR of over 17% during the forecast period.

Anabolic agents and biologics, such as Forteo by Eli Lilly and Prolia by Amgen, dominate the market, while bisphosphonates, like Bonviva/Boniva (ibandronic acid) by F. Hoffmann-La Roche and Aclasta/Zometa (zoledronate) by Novartis were major contributors to the overall revenue generated. Furthermore, the launch of some promising pipeline drugs with novel therapeutic actions is expected to positively influence market growth.

Competitive landscape and key vendors

Even though the osteoporosis drugs market in BRIC presents significant market opportunities for vendors, they need to offer therapies with better efficacy than bisphosphonates, such as Prolia by Amgen and Forteo/Forsteo by Eli Lilly, to stay competitive in the market.

Top vendors in this market are –

• Amgen
• Eli Lilly
• Merck
• Novartis

Other prominent vendors include Abiogen Pharma, Deltanoid Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, IMMD, Ligand Pharmaceuticals, Pantarhei Bioscience, Pfizer, PhytoHealth, Radius Health, Upsher-Smith Laboratories, and Zosano Pharma.

Segmentation of osteoporosis drugs market in BRIC by therapeutic class

• Antiresorptive medication
• Anabolic medication

Antiresorptive drugs limit bone loss by reducing the rate of bone resorption by osteoclasts, and these drugs are further categorized into five main classes such as bisphosphonate, denosumab, calcitonin, SERM, and estrogen.

Segmentation of osteoporosis drugs market in BRIC by line of therapy

• First-line therapy
• Second-line therapy

Bisphosphonates, which include alendronate, etidronate, risedronate, and zoledronic acid, are considered as a first-line preventive therapy in postmenopausal women with low bone density and glucocorticoid-induced osteoporosis.

Geographical segmentation of the osteoporosis drugs market in BRIC

• Brazil
• Russia
• India
• China

China is one of the fastest growing pharmaceutical markets in the BRIC countries and they were the largest revenue contributor of the overall market share in 2014. Factors such as unmet medical needs and the rise in the population of people aged 60 and above will drive market growth in the country.

Growth drivers, challenges, and upcoming trends: Osteoporosis drugs market

Technavio’s market research analysts evaluate upcoming trends, such as the shift toward anabolic treatment, which are currently under late and mid-stages of development. The introduction of new efficacious and safe anabolic treatments will be the major market driver in the management of osteoporosis.

This report provides a number of factors contributing to the adoption, limitations, and opportunities of the osteoporosis drugs market in BRIC nations. It also offers an analysis of each factor and an estimation of the extent to which the factors are likely to impact the overall market growth.

Key questions answered in the report include

• What will the market size and the growth rate be in 2019?
• What are the key factors driving the osteoporosis drugs market in BRIC nations?
• What are the key market trends impacting the growth of the osteoporosis drugs market in BRIC nations?
• What are the challenges to market growth?
• Who are the key vendors in the osteoporosis drugs market in BRIC nations?
• What are the market opportunities and threats faced by the vendors in the osteoporosis drugs market in BRIC nations?
• Trending factors influencing the market shares of Brazil, Russia, India, and China.
• What are the key outcomes of the five forces analysis of the osteoporosis drugs market in BRIC nations?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Osteoporosis Drugs Market 2015-2019
• Osteoporosis Drugs Market in the APAC Region 2015-2019
• Global Bone Densitometers Market 2014-2018
• Global Hepatitis Drugs Market 2015-2019
• Global Hyperphosphatemia Drugs Market 2015-2019